ALNY vs FER Comparison

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Ferrovial SE is a Spanish industrial company. The company organizes itself into four segments: Toll Roads, Airports, Construction, and Energy. The Toll Roads segment develops and operates toll roads globally. The Airports segment includes the Development, financing and operation of airports. The Construction segment Designs and executes all public and private works, including most notably the construction of public infrastructures. The Energy segment focuses on innovative solutions for promoting, constructing and operating energy generation and transmission infrastructures.